Passage BIO, Inc. (PASG) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: August 22, 2025
Passage BIO, Inc. (PASG) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
Passage BIO, Inc. (Stock Symbol: PASG)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
The organization employs approximately 111 professionals worldwide
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Market Capitalization: $24 million - Classified as a
small-cap investment offering high growth potential.
Return on Equity (ROE): -52.4% -
Below-average
shareholder return efficiency, indicating areas for operational improvement.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Passage BIO, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
Passage BIO, Inc. strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
Passage BIO, Inc. Stock Price Chart and Technical Analysis
Loading chart data...
Loading Passage BIO, Inc. interactive price chart and technical analysis...
Deep dive into Passage BIO, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if Passage BIO, Inc. stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For Passage BIO, Inc.: With a P/E ratio of -0.57, the market sees the stock as potentially undervalued.
P/E Ratio-0.57x
P/B Ratio0.63x
Market Cap$24M
EPS$-8.35
Book Value/Share$12.04
FCF/Share$-1.51
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently Passage BIO, Inc. converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For Passage BIO, Inc.: An ROE of -52.4% indicates room for improvement in shareholder value creation.
ROE-52.4%
ROA-47.4%
ROIC-48.8%
Understanding Financial Health Metrics
What these metrics mean: These ratios assess Passage BIO, Inc.'s ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For Passage BIO, Inc.: A current ratio of 10.30 indicates strong liquidity.
Current Ratio10.30x
Quick Ratio9.72x
D/E Ratio0.09x
Financial Leverage1.18x
Working Capital$296M
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal Passage BIO, Inc.'s ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For Passage BIO, Inc.: Free cash flow of $-167M indicates cash challenges that need attention.
Operating Cash Flow$-141M
Free Cash Flow$-167M
Capital Spending$-27M
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively Passage BIO, Inc. uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For Passage BIO, Inc.:
Understanding Financial Statement Data
What these metrics mean: Key figures from Passage BIO, Inc.'s income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For Passage BIO, Inc.:
Income Statement ($ Millions)
Operating Income$-71M
Net Income$-70M
R&D Expense$52M
Balance Sheet Highlights ($ Millions)
Total Current Assets$85M
Cash & Short-term Investments$80M
Total Liabilities$16M
Dividend & Shareholder Information
Shares Outstanding3M
Growth Metrics (YoY)
EPS Growth-179.4%
Passage BIO, Inc. (PASG) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Passage BIO, Inc. stock analysis.
Loading fundamental data...
Loading Passage BIO, Inc. comprehensive fundamental analysis and insider trading data...
Latest Passage BIO, Inc. Stock News & Market Analysis
Breaking news, analyst reports, and market updates affecting Passage BIO, Inc. (PASG) stock price and investment outlook.
Shares of Passage Bio, Inc. (PASG) have gained 31.5% over the past four weeks to close the last trading session at $7.59, but there could still be a solid upside left in the stock if short-term price ...
Shares of Passage Bio, Inc. Have increased 144.29% over the past quarter, and have gained 30.53% in the last year. On the other hand, the S&P 500 has only moved 12.57% and 27.72%, respectively.
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases ...
Furthermore, Passage Bio’s financial position is solid, with the company ending the third quarter of 2024 with $84.8 million in cash, which is anticipated to support operations through the ...
--Passage Bio, Inc., a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the ...
Passage Bio granted options to purchase 10,400 shares of common stock to this employee as material inducement to employment in accordance with Nasdaq Listing Rule 5635 (c) (4). The stock options ...
Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatment PHILADELPHIA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio ...
About Passage Bio, Inc. Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases.
Passage Bio Stock Up 8.2 % Shares of Passage Bio stock opened at $0.79 on Monday. Passage Bio has a twelve month low of $0.58 and a twelve month high of $1.79. The business has a 50-day moving ...
If you want to know who really controls Passage Bio, Inc. (NASDAQ:PASG), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, institutions will ...
Passage BIO, Inc. Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of Passage BIO, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
Frequently Asked Questions - Passage BIO, Inc. Stock Forecast
How accurate are Passage BIO, Inc. stock predictions?
Our AI model demonstrates 18% historical accuracy for PASG predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence Passage BIO, Inc. stock price forecasts?
Based on our AI analysis, Passage BIO, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are Passage BIO, Inc. forecasts updated?
Passage BIO, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced Passage BIO, Inc. Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Passage BIO, Inc. stock.
